Loading company…
Yongin-based South Korean biotech developing RNA therapeutics with its OliPass Peptide Nucleic Acid technology, founded in 2006.
OliPass Corporation was founded in 2006 and is headquartered in Yongin, South Korea. Its core product, OliPass Peptide Nucleic Acid, adds cationic lipid groups to peptide nucleic acids to improve cell permeability, enabling exon skipping in pre-mRNA for genetic disorders. It works with pharmaceutical and biotech partners under joint research and licensing agreements. The company raised KRW 14 billion in an IPO on September 10, 2019, selling 0.7 million shares at KRW 20,000 each, and CEO Shin Chung leads it.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in